Predict your next investment

Corporation
pierre-fabre.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

Funds

1

Partners & Customers

10

About Pierre Fabre

Pierre Fabre is a French pharmaceutical group. Founded and its headquarters still based in the South-west of France, Pierre Fabre has branches in countries and distribution agreements in over 130 countries. Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide.

Pierre Fabre Headquarter Location

Avenue Hoche

Paris, 75008,

France

+33 (0)5 63.62.38.50

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Pierre Fabre Investments

3 Investments

Pierre Fabre has made 3 investments. Their latest investment was in Aglaia Therapeutics as part of their Seed VC on September 9, 2021.

CBI Logo

Pierre Fabre Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/27/2021

Seed VC

Aglaia Therapeutics

$4.7M

Yes

2

4/8/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/10/2018

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/27/2021

4/8/2021

1/10/2018

Round

Seed VC

Series A

Corporate Minority

Company

Aglaia Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$4.7M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

Pierre Fabre Portfolio Exits

1 Portfolio Exit

Pierre Fabre has 1 portfolio exit. Their latest portfolio exit was Pierre Fabre - Elancyl on November 06, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/6/2020

Divestiture

1

Date

11/6/2020

Exit

Divestiture

Companies

Valuation

Acquirer

Sources

1

Pierre Fabre Acquisitions

2 Acquisitions

Pierre Fabre acquired 2 companies. Their latest acquisition was Igenica Biotherapeutics on May 24, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/24/2017

Series F

$85.73M

Asset Sale

1

1/15/2007

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2017

1/15/2007

Investment Stage

Series F

Companies

Subscribe to see more

Valuation

Total Funding

$85.73M

$99M

Note

Asset Sale

Subscribe to see more

Sources

1

10

Pierre Fabre Fund History

1 Fund History

Pierre Fabre has 1 fund, including Pierre Fabre Fund for Innovation.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/3/2016

Pierre Fabre Fund for Innovation

1

Closing Date

2/3/2016

Fund

Pierre Fabre Fund for Innovation

Fund Type

Status

Amount

Sources

1

Pierre Fabre Partners & Customers

10 Partners and customers

Pierre Fabre has 10 strategic partners and customers. Pierre Fabre recently partnered with Y-Biologics on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/7/2021

Licensor

Y-Biologics

South Korea

Y-Biologics, Pierre Fabre Enter Immuno-oncology Alliance

Young Woo Park , CEO of Y-Biologics , said , `` We are very pleased to sign our first license agreement with Pierre Fabre .

2

7/7/2021

Vendor

Atos

France

2

4/8/2021

Licensee

Valenza Biotech

United States

ValenzaBio Advances Pipeline of Antibody Therapeutics Toward Clinical Development for Autoimmune and Inflammatory Diseases

ValenzaBio has entered into a license and commercialization agreement with Pierre Fabre for a monoclonal antibody directed to insulin-like growth factor 1 receptor , which ValenzaBio plans to progress into the clinic in the first half of 2022 .

3

2/25/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

11/23/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/7/2021

7/7/2021

4/8/2021

2/25/2021

11/23/2020

Type

Licensor

Vendor

Licensee

Licensor

Partner

Business Partner

Y-Biologics

Atos

Valenza Biotech

Country

South Korea

France

United States

Subscribe to see more

Subscribe to see more

News Snippet

Y-Biologics, Pierre Fabre Enter Immuno-oncology Alliance

Young Woo Park , CEO of Y-Biologics , said , `` We are very pleased to sign our first license agreement with Pierre Fabre .

ValenzaBio Advances Pipeline of Antibody Therapeutics Toward Clinical Development for Autoimmune and Inflammatory Diseases

ValenzaBio has entered into a license and commercialization agreement with Pierre Fabre for a monoclonal antibody directed to insulin-like growth factor 1 receptor , which ValenzaBio plans to progress into the clinic in the first half of 2022 .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

3

10

10

Pierre Fabre Team

9 Team Members

Pierre Fabre has 9 team members, including former Chief Executive Officer, Olivier Bohuon.

Name

Work History

Title

Status

Olivier Bohuon

Chief Executive Officer

Former

Frederic Duchesne

Chief Executive Officer

Former

Christophe Durand

President, Chief Operating Officer

Former

Emmanuel SCHMIDT

Star Service, Groupe SEB, and Mazars

Chief Financial Officer

Former

Francois Viargues

Chief Financial Officer

Former

Name

Olivier Bohuon

Frederic Duchesne

Christophe Durand

Emmanuel SCHMIDT

Francois Viargues

Work History

Star Service, Groupe SEB, and Mazars

Title

Chief Executive Officer

Chief Executive Officer

President, Chief Operating Officer

Chief Financial Officer

Chief Financial Officer

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.